Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Exclusion Criteria

• •Performance status - Karnofsky 50-100% (over age 10)
• •Performance status - Lansky 50-100% (age 10 and under)
• •At least 2 months
• •Absolute neutrophil count at least 1,000/mm\^3
• •Platelet count at least 75,000/mm\^3 (transfusion independent)
• •Hemoglobin at least 8.0 g/dL (transfusion allowed)
• •No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement
• •Bilirubin no greater than 1.5 times normal
• •SGPT no greater than 5 times normal
• •Albumin at least 2 g/dL
• •Creatinine no greater than 1.5 times normal
• •Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal
• •Shortening fraction at least 27% by echocardiogram
• •Ejection fraction at least 50% by MUGA
• •Stable neurologic deficits within the past 2 weeks for patients with CNS tumors
• •CNS toxicity less than grade 2
• •No active graft-versus-host disease
• •No active uncontrolled infection or other serious medical condition
• •No uncontrolled diabetes mellitus
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •At least 7 days since prior biologic therapy and recovered
• •Prior bone marrow or stem cell transplantation allowed
• •At least 6 months since prior allogeneic stem cell transplantation
• •At least 1 week since prior growth factors
• •No concurrent immunomodulating agents
• •At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
• •No other concurrent chemotherapy
• •Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks prior to study
• •Concurrent corticosteroids allowed only for increased intracranial pressure in patients with CNS tumors
• •At least 2 weeks since prior local (small port) palliative radiotherapy
• •At least 6 months since prior radiotherapy to 50% or more of the pelvis
• •At least 6 months since prior craniospinal radiotherapy
• •At least 6 weeks since other prior substantial bone marrow radiotherapy
• •Recovered from prior radiotherapy
• •No concurrent radiotherapy except localized palliative radiotherapy
• •No concurrent anticonvulsants